Asimov and Sidewinder partner on cell line development: a 4-chain bispecific antibody reaches clonal titers above 10 g/L in a platform fed-batch process
Synopsis
Asimov announced a cell line development partnership with Sidewinder Therapeutics and delivered a cell line for Sidewinder's 4-chain bispecific antibody candidate for solid tumors. Such complex molecules are hard to express, and Sidewinder needed both the required expression level and consistent product quality. Asimov ran the custom program with its CHO Edge system, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, its AI-driven genetic design software; in a platform fed-batch process the cell line achieved clonal titers of over 10 g/L.
Interpretation
Asimov formed a cell line development partnership with Sidewinder Therapeutics and delivered a cell line for Sidewinder's 4-chain bispecific antibody candidate for solid tumors, as part of a broader multi-product collaboration. Complex molecules such as a 4-chain bispecific can be challenging to express, and Sidewinder needed to reach the required expression levels while achieving consistent product quality, so it sought a partner with the technical capabilities for cell line development. In a platform fed-batch process the cell line achieved clonal titers of over 10 g/L; Asimov CEO Alec Nielsen said achieving such high titers for this molecule reflects the strength of the team and the CHO Edge System.
The cell line work relied on Asimov's CHO Edge system, which combines host-cell engineering, gene integration tools, a parts library and AI design software into one workflow. CHO Edge combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, Asimov's AI-driven genetic design software, for custom cell line development programs. The collaboration ran a custom cell line development program for Sidewinder's 4-chain bispecific antibody, aimed at the required expression levels and quality attributes.
Perspective
The demonstrated scope is a completed custom cell line development for Sidewinder's 4-chain bispecific antibody candidate, with clonal titers above 10 g/L measured in a platform fed-batch process; Sidewinder says it is progressing toward the clinic with this cell line.
The announcement does not state the specific process conditions behind the titer, the quality attribute data, or a timeline for the cell line to enter the clinic; the over 10 g/L figure is a clonal titer in a platform fed-batch process, not a clinical or commercial manufacturing result.